Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VSJ-110 for Allergic Conjunctivitis
Go back to Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VSJ-110 for Allergic Conjunctivitis| Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) | Delayed: 5.25 -0.08 (1.5%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.33 | 52 Week High | $18.00 | |||
| Open | $5.29 | 52 Week Low | $6.91 | |||
| Day High | $5.35 | P/E | N/A | |||
| Day Low | $5.22 | EPS | $-0.67 | |||
| Volume | 193,285 | |||||
